These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 2539499)

  • 1. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.
    Pevear DC; Fancher MJ; Felock PJ; Rossmann MG; Miller MS; Diana G; Treasurywala AM; McKinlay MA; Dutko FJ
    J Virol; 1989 May; 63(5):2002-7. PubMed ID: 2539499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14.
    Sherry B; Mosser AG; Colonno RJ; Rueckert RR
    J Virol; 1986 Jan; 57(1):246-57. PubMed ID: 2416951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
    Dewindt B; van Eemeren K; Andries K
    Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhinovirus chemotherapy.
    Patick AK
    Antiviral Res; 2006 Sep; 71(2-3):391-6. PubMed ID: 16675037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.
    Rosenwirth B; Oren DA; Arnold E; Kis ZL; Eggers HJ
    Antiviral Res; 1995 Jan; 26(1):65-82. PubMed ID: 7741522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.
    Ninomiya Y; Ohsawa C; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Virology; 1984 Apr; 134(2):269-76. PubMed ID: 6100571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
    Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
    J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptidyl diazomethyl ketones inhibit the human rhinovirus 3C protease: effect on virus yield by partial block of P3 polyprotein processing.
    Murray MA; Janc JW; Venkatraman S; Babé LM
    Antivir Chem Chemother; 2001 Sep; 12(5):273-81. PubMed ID: 11900346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mode of action of 2-furylmercury chloride, an anti-rhinovirus compound.
    Verheyden B; Andries K; Rombaut B
    Antiviral Res; 2004 Mar; 61(3):189-94. PubMed ID: 15168800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the Mengo virion. VII. Crystallization and preliminary X-ray diffraction analysis.
    Boege U; Scraba DG; Hayakawa K; James MN; Erickson JW
    Virology; 1984 Oct; 138(1):162-7. PubMed ID: 6093358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound.
    Moeremans M; De Raeymaeker M; Daneels G; De Brabander M; Aerts F; Janssen C; Andries K
    Antimicrob Agents Chemother; 1992 Feb; 36(2):417-24. PubMed ID: 1318682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
    Fox MP; McKinlay MA; Diana GD; Dutko FJ
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.
    Shepard DA; Heinz BA; Rueckert RR
    J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14.
    Badger J; Minor I; Kremer MJ; Oliveira MA; Smith TJ; Griffith JP; Guerin DM; Krishnaswamy S; Luo M; Rossmann MG
    Proc Natl Acad Sci U S A; 1988 May; 85(10):3304-8. PubMed ID: 2835768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
    Heinz BA; Rueckert RR; Shepard DA; Dutko FJ; McKinlay MA; Fancher M; Rossmann MG; Badger J; Smith TJ
    J Virol; 1989 Jun; 63(6):2476-85. PubMed ID: 2542566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the direct involvement of the rhinovirus canyon in receptor binding.
    Colonno RJ; Condra JH; Mizutani S; Callahan PL; Davies ME; Murcko MA
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5449-53. PubMed ID: 2840661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human rhinovirus 14 complexed with antiviral compound R 61837.
    Chapman MS; Minor I; Rossmann MG; Diana GD; Andries K
    J Mol Biol; 1991 Feb; 217(3):455-63. PubMed ID: 1847215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of human rhinovirus serotype 2 against pH-induced conformational change by antiviral compounds.
    Gruenberger M; Pevear D; Diana GD; Kuechler E; Blaas D
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():431-3. PubMed ID: 1847178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a high-throughput human rhinovirus infectivity cell-based assay for identifying antiviral compounds.
    Phillips T; Jenkinson L; McCrae C; Thong B; Unitt J
    J Virol Methods; 2011 May; 173(2):182-8. PubMed ID: 21300110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.
    Patick AK; Brothers MA; Maldonado F; Binford S; Maldonado O; Fuhrman S; Petersen A; Smith GJ; Zalman LS; Burns-Naas LA; Tran JQ
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2267-75. PubMed ID: 15917520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.